

Mol Percent Report

Sample ID: 01402018 (initiated 1/15/99 7:03am) BASELINE CORRECTED

Turntable Position:	6 C	Sampling Interval:	1.0 sec
Data Start	: 3.00 min	Samples In Run	: 72
Data Duration	: 16.00 min	Operator ID	:
Peak Ht Thrshld	: 3000 uAU	Int. Std. Amt	: 250 pmol

Calibration File	: 14JANCAL	(initiated 1/15/99 9:44am)
Reference Time	: 0.00 min	(No ISTD Peak Specified)
Reference Offset 1:	-0.02 min	
Reference Offset 2:	0.00 min	

Integration Interval: 0.0 to 16.0 min

PEAK ID	RET. TIME min	PMOL BY HEIGHT	PMOL correc. INT STD	MOL %
ASX	2.30	562.99	0.00	29.02
GLX	2.70	1377.05	0.00	70.98

TOTAL PMOLS RECOVERED 1940.04

Minimum Peak Threshold: 3000 uAU (53 peaks below threshold)
 (8 peaks found)
 (2 peaks matched)

Figure 1B.

Amino acid analysis of the polypeptide

Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-
 Metal Complexes and Compositions, Methods of Making, and
 Methods of Using Same"

Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03


Express Mail No. EL 872 048 512 US

1/10


T04230-03T0460

10/22/80 08:04:50


Poly(glutamic/aspartic acid), (in DMSO)



Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"
Agent: Mary A. Gilbreth, Ph.D. Reg. No. 45,775
Atty Docket: 27300/03
Express Mail No. EL 872 048 512 US
2/10




Pt(II) Complex



Pt(IV) Complex

Figure 2.

Structures of platinum(II) and platinum(IV)-poly(dipeptide) complexes



Galbraith Laboratories, Inc.

Accuracy with Speed - Since 1950

LABORATORY REPORT

SAMPLE ID	LAB ID	ANALYSIS	RESULT(S)
DACH	I-5746	Platinum	44.60 %
PPAP	I-5747	Platinum	16.11 %
PDDP	I-5748	Platinum	17.64 %

702230-08704660

Figure 3

Elemental analysis of platinum-poly(dipeptide) complexes for Pt(II)(PDDP), Pt(IV)(PPAP) and cis-1,2-DACH-Pt SO₄(DACH)

This report shall not be reproduced, except in full, without the written approval of the laboratory.

P. O. Box 51610, Knoxville, TN 37950-1610 • 2323 Sycamore Drive, Knoxville, TN 37921-1700
Toll-Free: 877-445-8757 • Tel: 865-546-1335 • Fax: 865-546-7209
Internet: <http://www.galbraith.com> • Email: labinfo@galbraith.com


Inventor: William W. Zuo, et al. Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"

Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03

Express Mail No. EL 872 048 512 US

Effect of PDDP & CDDP on Inhibition of Human Sarcoma Cells (HT1080) at 48 Hours



Effect of PDDP & CDDP on Inhibition of Human Sarcoma Cells (HT1080) at 72 Hours




Figure 4A

In vitro cell culture assay of cisplatin(CDDP) and poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex(PDDP) in human sarcoma

Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"


Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03

Express Mail No. EL 872 048 512 US

5/10

Effect of PDDP & CDDP on Inhibition of Human Prostate Cancer Cells (A10) at 48 Hours



Effect of PDDP & CDDP on Inhibition of Human Prostate Cancer Cells (A10) at 96 Hours




Figure 4-B

In vitro cell culture assay of cisplatin(CDDP) and poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex(PDDP) in human prostate cancer

Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"


Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03

Express Mail No. EL 872 048 512 US

6/10

Effect of PDDP & CDDP on Inhibition of Human Prostate Cancer Cells (PC3) at 48 Hours



Effect of PDDP & CDDP on Inhibition of Human Prostate Cancer Cells (PC3) at 96 Hours




Figure 5C

In vitro cell culture assay of cisplatin(CDDP) and poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex(PDDP) in human prostate cancer

Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"

Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03

Express Mail No. EL 872 048 512 US

7/10

Anti-tumor Activity of PDDP Against Rats Bearing Breast Tumors (13762)




Figure 5

In vivo anti-tumor activity of an inventive poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex (PDDP) compared to control against rats bearing breast tumors.





Figure 6


The specific cellular target expression changes at 48 hours post treatment of poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex (PDDP), cisplatin (CDDP) and saline (control)



Histopathological slide of the breast tumor (13762) at 48 hours post treatment of PDDP



Histopathological slide of the breast tumor (13762) at 48 hours post treatment of CDDP



Histopathological slide of the breast tumor (13762) at 48 hours post treatment of Saline

Figure 7

The histopathological changes of breast tumors (13762) at 48 hours post treatment of poly(glutamate/aspartate) acid-1,2-DACH-Pt(II) complex (PDDP), cisplatin (CDDP) and Saline

Inventor: William W. Zuo, et al Title: "Anticancer Polypeptide-Metal Complexes and Compositions, Methods of Making, and Methods of Using Same"

Agent: Mary A. Gilbreth, Ph.D. Reg No. 45,775

Atty Docket: 27300/03

Express Mail No. EL 872 048 512 US

10/10

10/22/03 08:10:46